Amneal Pharmaceuticals (AMRX) Change in Receivables (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Change in Receivables of -$44.0 million for Q1 2026, down 108.12% year-over-year from $542.1 million in Q1 2025, and down 525.74% quarter-over-quarter from $10.3 million in Q4 2025.
Amneal Pharmaceuticals (AMRX) Change in Receivables (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Change in Receivables history runs 10 years deep, the most recent figure standing at -$44.0 million for Q1 2026.
- In Q1 2026, Change in Receivables fell 108.12% year-over-year to -$44.0 million; the TTM figure through Mar 2026 stood at $97.7 million (up 13.19% YoY), while the FY2025 annual figure was $120.6 million, down 25.87% from the prior year.
- Change in Receivables for Q1 2026 stood at -$44.0 million, down from $10.3 million in the prior quarter.
- The five-year high for Change in Receivables was $150.8 million in Q2 2022, with the low at -$196.0 million in Q1 2023.
- The 5-year median for Change in Receivables is $17.9 million (2023), against an average of $11.3 million.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables tumbled 221.71% in 2024, then surged 455.83% in 2025.
- Amneal Pharmaceuticals' Change in Receivables stood at $113.3 million in 2022, then plunged by 168.18% to -$77.2 million in 2023, then jumped by 137.04% to $28.6 million in 2024, then plunged by 63.86% to $10.3 million in 2025, then slumped by 525.74% to -$44.0 million in 2026.
- Business Quant data shows AMRX's Change in Receivables at -$44.0 million in Q1 2026, $10.3 million in Q4 2025, and $77.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Amneal Pharmaceuticals | 5.72 Bn | 5.59 Bn | 334.51 Mn | 169.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 169.78 Mn |
| Jun 30, 2026 | 169.78 Mn |
| Mar 31, 2026 | -44.01 Mn |
| Mar 31, 2026 | -44.01 Mn |
| Dec 31, 2025 | 10.34 Mn |
| Dec 31, 2025 | 10.34 Mn |
| Sep 30, 2025 | 77.61 Mn |
| Sep 30, 2025 | 77.61 Mn |
| Jun 30, 2025 | 53.76 Mn |
| Jun 30, 2025 | 53.76 Mn |
| Mar 31, 2025 | -21.15 Mn |
| Mar 31, 2025 | -21.15 Mn |
| Dec 31, 2024 | 28.61 Mn |
| Dec 31, 2024 | 28.61 Mn |
| Sep 30, 2024 | -21.81 Mn |
| Sep 30, 2024 | -21.81 Mn |
| Jun 30, 2024 | 100.67 Mn |
| Jun 30, 2024 | 100.67 Mn |
| Mar 31, 2024 | 55.17 Mn |
| Mar 31, 2024 | 55.17 Mn |